难治性甲状腺癌免疫治疗的研究进展  

Advances of immunotherapy in refractory thyroid carcinoma

作　　者：宋建鲁 闫廷 杨治力[1] Song Jianlu;Yan Ting;Yang Zhili(Department of Thyroid,Parathyroid,Breast&Hernia Surgery,Shanghai Jiao Tong University Affiliated Sixth People’s Hospital,Shanghai 200233,China)

机构地区：[1]上海交通大学附属第六人民医院甲乳疝外科,200233

出　　处：《中华内分泌外科杂志》2020年第1期80-82,共3页Chinese Journal of Endocrine Surgery

基　　金：国家自然科学基金(81472499)。

摘　　要：近年来,甲状腺癌(thyroid cancer,TC)的发病率明显升高,已成为内分泌系统最常见的恶性肿瘤。虽大多数TC可通过早期手术和放射性131I获得良好的预后,但包括碘抵抗性分化型甲状腺癌(radioiodine-refractory differentiated thyroid cancer,RAIR-DTC)和甲状腺未分化癌(anaplastic thyroid carcinoma,ATC)在内的难治性甲状腺癌(refractory thyroid carcinoma,RTC)仍缺乏提高长期整体生存率的治疗手段。免疫治疗是继手术、放化疗及靶向治疗后的新兴疗法,目前已在多种恶性肿瘤的治疗中展现出巨大潜力,有望为RTC提供一种新的选择。In recent years,the incidence of thyroid cancer has increased significantly and it has become the most common malignant tumor of the endocrine system.Despite the favorable prognosis of most thyroid cancers,a small fraction of differentiated thyroid carcinomas and almost all anaplastic thyroid carcinomas grouped together as"refractory thyroid carcinoma(RTC)",remain resistant to standard treatment options,including early surgery and radioactive 131I treatment.It is unclear what treatment is best for cases of RTC.Tumor immunotherapy is an emerging treatment after surgery,radiotherapy,chemotherapy and targeted therapy.Immunotherapy has shown great potential in various malignant tumors and may provide a new choice for the treatment of RTC.

关 键 词：难治性甲状腺癌 肿瘤免疫治疗 免疫检查点阻断剂 个性化肿瘤疫苗 CAR-T 

分 类 号：R653[医药卫生—外科学] R736.1[医药卫生—临床医学]